false 0001422142 0001422142 2024-09-26 2024-09-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2024

 

 

AADI BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38560   61-1547850
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

17383 Sunset Boulevard, Suite A250

Pacific Palisades, California

   90272
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (424) 744-8055

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   AADI   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Information.

As previously reported, in June 2022, EOC Pharma (Hong Kong) Limited (“EOC”) filed a Request for Arbitration with the International Chamber of Commerce’s International Court of Arbitration against Aadi Bioscience, Inc. (the “Company”). In the Request for Arbitration, EOC claimed that the Company breached certain provisions of the license agreement between EOC and the Company, dated December 8, 2020 (the “EOC License Agreement”), including failing to provide certain manufacturing information to EOC. As a result, EOC sought monetary damages against the Company.

On September 26, 2024, the arbitration panel issued a Final Award which, among other things, found and concluded that the Company did not breach the EOC License Agreement and accordingly is not liable for any damages to EOC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      AADI BIOSCIENCE, INC.
Dated: September 30, 2024      

/s/ Scott Giacobello

      Scott Giacobello
      Chief Financial Officer
v3.24.3
Document and Entity Information
Sep. 26, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001422142
Document Type 8-K
Document Period End Date Sep. 26, 2024
Entity Registrant Name AADI BIOSCIENCE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38560
Entity Tax Identification Number 61-1547850
Entity Address, Address Line One 17383 Sunset Boulevard
Entity Address, Address Line Two Suite A250
Entity Address, City or Town Pacific Palisades
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90272
City Area Code (424)
Local Phone Number 744-8055
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol AADI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Aadi Bioscience (NASDAQ:AADI)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Aadi Bioscience.
Aadi Bioscience (NASDAQ:AADI)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Aadi Bioscience.